# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-19
**æ›´æ–°æ—¶é—´**: 2026-01-19 14:40
**æ–°é—»æ•°é‡**: 103

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### æœ¬å‘¨æ¦‚è§ˆ

æœ¬å‘¨åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºç›‘ç®¡å®¡æ‰¹ä¸é‡ç£…è¯ç‰©è¿›å±•ã€‚FDAå¯¹Travereçš„Filspariå…³é”®é€‚åº”ç—‡å®¡æ‰¹å»¶æœŸå¼•å‘å…³æ³¨ï¼ŒåŒæ—¶è¯ºå’Œè¯ºå¾·åŸºé‡‘ä¼šå®£å¸ƒå‘BioInnovation InstituteæŠ•å…¥è¶…8.5äº¿ç¾å…ƒä»¥æ¨åŠ¨ç”Ÿå‘½ç§‘å­¦åˆ›æ–°ã€‚æ­¤å¤–ï¼Œç¤¼æ¥å’Œè¯ºå’Œè¯ºå¾·åœ¨å£æœGLP-1è¯ç‰©é¢†åŸŸçš„ç«äº‰åŠ å‰§ï¼Œç¤¼æ¥é¢„è®¡å…¶è‚¥èƒ–ç—‡è¯ç‰©å°†åœ¨ç¬¬äºŒå­£åº¦è·å¾—FDAå†³å®šã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. FDA delays decision on Travere's Filspari in key kidney disease indication** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAå¯¹Travereçš„Filspariå…³é”®è‚¾ç—…é€‚åº”ç—‡å®¡æ‰¹å»¶æœŸï¼Œè¯¥é€‚åº”ç—‡é¢„è®¡æœ‰20äº¿ç¾å…ƒé”€å”®å³°å€¼æœºä¼šï¼Œå¯¹å…¬å¸å’Œè‚¾ç—…æ²»ç–—é¢†åŸŸå½±å“é‡å¤§ã€‚

**4. Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - è¯ºå’Œè¯ºå¾·åŸºé‡‘ä¼šæ‰¿è¯ºåœ¨2026å¹´è‡³2035å¹´é—´å‘BioInnovation InstituteæŠ•å…¥55äº¿ä¸¹éº¦å…‹æœ—ï¼ˆçº¦8.57äº¿ç¾å…ƒï¼‰ï¼Œæ˜¯ç”Ÿå‘½ç§‘å­¦é¢†åŸŸé‡å¤§é•¿æœŸæŠ•èµ„ã€‚

**18. Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill** â­â­â­â­
   - ç±»åˆ«: æ–°è¯ç ”å‘
   - ç¤¼æ¥é¢„è®¡å…¶å£æœè‚¥èƒ–ç—‡è¯ç‰©orforglipronå°†åœ¨ç¬¬äºŒå­£åº¦è·å¾—FDAå†³å®šï¼ŒåŠ å‰§äº†ä¸è¯ºå’Œè¯ºå¾·åœ¨GLP-1å£æœè¯ç‰©å¸‚åœºçš„ç«äº‰ã€‚

**6. JPM26: AstraZeneca's $80B revenue target 'very much within reach,' CFO says** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - é˜¿æ–¯åˆ©åº·CFOè¡¨ç¤ºå…¬å¸2030å¹´800äº¿ç¾å…ƒè¥æ”¶ç›®æ ‡â€œè§¦æ‰‹å¯åŠâ€ï¼Œåæ˜ äº†å¤§å‹è¯ä¼å¯¹æœªæ¥å¢é•¿çš„å¼ºåŠ²ä¿¡å¿ƒã€‚

**2. Makary talks FDA's plans to combat China's biotech growth** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå±€é•¿è¡¨ç¤ºå°†è°ƒæ•´IæœŸä¸´åºŠè¯•éªŒè§„å®šä»¥åŠ é€Ÿç¾å›½åˆ›æ–°ï¼Œä»¥åº”å¯¹ä¸­å›½ç”Ÿç‰©ç§‘æŠ€æŠ•èµ„å’Œè®¸å¯äº¤æ˜“çš„å¿«é€Ÿå¢é•¿ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): å£æœGLP-1è¯ç‰©ç«äº‰æ¿€çƒˆï¼Œç¤¼æ¥é¢„è®¡å…¶è‚¥èƒ–ç—‡è¯ç‰©orforglipronå°†åœ¨ç¬¬äºŒå­£åº¦è·å¾—FDAå†³å®šï¼›Scribe Therapeuticsè®¡åˆ’ä»Šå¹´å¤å­£æµ‹è¯•å…¶åŸºäºCRISPRçš„é™èƒ†å›ºé†‡ç–—æ³•ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): Argenxå·²å‘FDAæäº¤VYVGARTç”¨äºè¡€æ¸…é˜´æ€§gMGçš„è¡¥å……ç”³è¯·ï¼Œå¹¶è·å¾—å—ç†ï¼›FDAå¯¹ç‰¹æœ—æ™®æ”¿åºœå¿«é€Ÿé€šé“è®¡åˆ’ä¸­çš„ä¸¤ç§è¯ç‰©å› å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§æ‹…å¿§è€Œå»¶è¿Ÿå®¡æŸ¥ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

å…³æ³¨FDAä¸è¯ºå’Œè¯ºå¾·å°±å…¶å°ç¬¬å®‰çº³å·é—®é¢˜å·¥å‚çš„ä¼šè®®è¿›å±•ï¼›ç•™æ„Agomabå’ŒSpyGlass Pharmaçš„IPOç”³è¯·åç»­ï¼Œä»¥åŠæŠ•èµ„è€…å¯¹ç”Ÿç‰©ç§‘æŠ€IPOå¸‚åœºæƒ…ç»ªçš„å˜åŒ–ï¼›æŒç»­è·Ÿè¸ªå£æœGLP-1è¯ç‰©ï¼ˆå¦‚è¯ºå’Œè¯ºå¾·çš„Wegovyç‰‡å‰‚å’Œç¤¼æ¥çš„orforglipronï¼‰çš„å¸‚åœºè¡¨ç°å’Œç›‘ç®¡åŠ¨æ€ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 41 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ FDA delays decision on Travere's Filspari in key kidney disease indication

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 10:44
- **é‡è¦æ€§**: â­â­â­â­

> Much is riding on Travere Therapeuticsâ€™ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis (FSGS). The indication represents a $2 billion peak sales opportunity in the U.S. alone, according to Leerink Partners. So it was with some trepidation that Travere revealed that the FDA has postponed its decision on Filspari in FSGS by three months to April 13.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-delays-decision-traveres-filspari-2b-kidney-disease-indication)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 14:12
- **é‡è¦æ€§**: â­â­â­â­

> The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ JPM26: AstraZeneca's $80B revenue target 'very much within reach,' CFO says

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-13 23:32
- **é‡è¦æ€§**: â­â­â­

> While the $80 billion revenue target AstraZeneca set for 2030 is already "very much within reach," Chief Financial Officer Aradhana Sarin said the company would grow even more confident if it can repeat the phase 3 success rate it saw last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says)

---

### ğŸ‡ºğŸ‡¸ Drug approvals went from crawl to sprint in 2025

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:37
- **é‡è¦æ€§**: â­â­

> On this episode of "The Top Line," we dig into how turmoil at the FDA impacted drug approvals in 2025.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/drug-approvals-went-crawl-sprint-2025)

---

### ğŸ‡ºğŸ‡¸ FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 11:11
- **é‡è¦æ€§**: â­â­

> The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures which can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-tells-sanofi-gsk-az-and-csl-include-warning-childhood-seizures-flu-shots)

---

### ğŸ‡ºğŸ‡¸ FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 11:21
- **é‡è¦æ€§**: â­â­

> The steady stream of FDA untitled letters that began in September is showing no signs of letting up in the new year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/fda-chides-beone-immunitybio-promo-materials-first-untitled-letters-2026)

---

### ğŸ‡ºğŸ‡¸ JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 01:31
- **é‡è¦æ€§**: â­â­

> With Xtandi set to lose U.S. patent protection next year, Astellasâ€™ CEO fielded questions this week about his companyâ€™s dealmaking strategy ahead of the loss. Despite continuing to hunt for external innovation, helmsman Naoki Okamura does not want Astellas to make acquisitions for the sole purpose of preventing a revenue decline.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astellas-ceo-resists-rescue-bd-6b-xtandi-patent-cliff-nears)

---

### ğŸ‡ºğŸ‡¸ BD budgets $110M to expand Neb. syringe production

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 08:06
- **é‡è¦æ€§**: â­â­

> Becton, Dickinson and Company will shell out $110 million to expand prefillable syringe production at its Columbus, Nebraska, manufacturing plant. The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical reshoring in the U.S., the company said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/becton-dickinson-budgets-110m-expand-nebraska-syringe-production-plant)

---

### ğŸ‡ºğŸ‡¸ JPM26: Jazz's $200M voucher sale shows drumbeat of rising prices isn't stopping

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 15:23
- **é‡è¦æ€§**: â­â­

> Even in the era of the FDA's Commissioner's National Priority Voucher program, Jazz Pharmaceuticals is showing that traditional priority review vouchers can catch a pretty penny.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm26-jazzs-prv-sale-200m-shows-drum-beat-rising-prv-prices-isnt-stopping)

---

### ğŸ‡ºğŸ‡¸ Amneal and VantAI unveil fresh branding to kick off 2026 plans

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 11:05
- **é‡è¦æ€§**: â­â­

> Amneal Pharmaceuticals and VantAI have joined the ranks of companies to decide that a new year demands a new look, each unveiling fresh branding aligned with their respective plans for 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/amneal-and-vantai-unveil-fresh-branding-kick-2026-plans)

---

### ğŸ‡ºğŸ‡¸ STAT+: FDA delays reviews for two drugs in new voucher program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:36
- **é‡è¦æ€§**: â­â­

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:30
- **é‡è¦æ€§**: â­â­

> Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines over possible legal risks

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a change in obesity drug warnings, FDA approvals, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-14 14:20
- **é‡è¦æ€§**: â­â­

> After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight loss drugs

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/14/obesity-weight-suicide-illumina-antibiotics-pfizer-lilly-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a â€˜breachedâ€™ FDA firewall, an AbbVie pricing deal with Trump, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-13 14:22
- **é‡è¦æ€§**: â­â­

> A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers â€œhas been breached"

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/13/fda-trump-abbvie-cvs-hiv-lilly-nvidia-abortion/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: On Day 1 of JPM, no blockbuster headlines, but biotech newsmakers still move markets

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-12 20:52
- **é‡è¦æ€§**: â­â­

> So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs â€” the most ever for the pre-JPM timespan.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/12/jpm-2026-day-1-top-stories-bridgebio-moderna-eli-lilly-readout-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: With a grin â€” and tight lips â€” Revolution Medicinesâ€™ CEO faces questions about acquisition

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-12 20:33
- **é‡è¦æ€§**: â­â­

> Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he probably wasnâ€™t going to answer. He did well.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/12/revolution-medicines-merck-jpm-conference/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:16
- **é‡è¦æ€§**: â­

> Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us)

---

### ğŸ‡ºğŸ‡¸ Lenz ups Vizz visibility with DTC campaign starring Sarah Jessica Parker

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 11:18
- **é‡è¦æ€§**: â­

> As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded partnership for its Vizz prescription eye drops.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/lenz-ups-vizz-visibility-dtc-campaign-starring-sarah-jessica-parker)

---

### ğŸ‡ºğŸ‡¸ From approval to value: Why evidence storytelling now matters

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 15:46

> RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisionsâ€”and why clear communication is essential.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/approval-value-why-evidence-storytelling-now-matters)

---

### ğŸ‡ºğŸ‡¸ After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:29

> Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next)

---

### ğŸ‡ºğŸ‡¸ JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:52

> With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;A plays to expand in-house.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming)

---

### ğŸ‡ºğŸ‡¸ AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;Jâ€™s Tremfya in hot pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:49

> For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AbbVieâ€™s bispecific play, Illuminaâ€™s China import efforts and pharma execsâ€™ JPM comments

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 10:47

> In this week's Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina's CEO detailed the company's efforts to work with authorities in China. In addition, Astellas CEO Naoki Okamura updated the audience at Fierce JPM Week on the company's approach to dealmaking.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fierce-pharma-asia-abbvies-bispecific-play-illuminas-china-import-efforts-and-pharma-execs)

---

### ğŸ‡ºğŸ‡¸ Former Emergent CEO Kramer faces insider trading allegations in NY

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:21

> New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues at a plant in Baltimore. As part of the action, New York also announced a $900,000 million settlement with the company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny)

---

### ğŸ‡ºğŸ‡¸ JPM26: Whatâ€™s in a biopharma? CEO says Teva has the goods

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 15:17

> Under CEO Richard Francis, Teva has long been looking to reframe itself as an innovative drugmaker on par with industry peers. Now, Francis says the company is on track to complete its transformation into a leading innovative biopharma company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm-2026-biosimilars-biopharma-teva-walks-walk-2026)

---

### ğŸ‡ºğŸ‡¸ Trump takes aim at insurance industry, drug prices in unveiling 'The Great Healthcare Plan'

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 12:47

> President Donald Trump has hinted at "concepts of a plan" for healthcare for months as legislators debate the future of key subsidies under the Affordable Care Act, and on Thursday the White House unveiled a more concrete version of their vision for health policy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/regulatory/trump-takes-aim-insurance-industry-unveiling-great-healthcare-plan)

---

### ğŸ‡ºğŸ‡¸ After succeeding in combo with Darzalex, J&amp;J's Tecvayli shines as solo act

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 07:45

> Just a month after Johnson &amp; Johnson reported a successful study pairing its blood cancer treatments Tecvayli and Darzalex, the company has revealed another trial win. This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care in a group of multiple myeloma patients resistant to anti-CD38 therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-succeeding-combo-darzalex-jjs-tecvayli-shines-solo-act)

---

### ğŸ‡ºğŸ‡¸ Hologic sets a screen to block cervical cancer with WNBA's Erica Wheeler

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 06:58

> Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the guard at the center of a drive to frame testing as the â€œUltimate Defense.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/hologic-sets-screen-block-cervical-cancer-basketball-star)

---

### ğŸ‡ºğŸ‡¸ Bayer taps Gabrielle Union-Wade as face of menopause med Lynkuet

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 15:06

> To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bayer-taps-gabrielle-union-wade-face-menopause-med-lynkuet)

---

### ğŸ‡ºğŸ‡¸ JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 14:30

> With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is now enjoying more clarity from the federal government than at the same time last year. But several concerns still linger for the French pharma as the calendar turns to 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/jpm26-after-important-year-sanofi-looks-ahead-remaining-federal-challenges)

---

### ğŸ‡ºğŸ‡¸ JPM26: Novo Nordisk CEO reflects on 'curse of a leader' as company looks to reassert GLP-1 footing

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-14 09:32

> The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out for 2026, new CEO Maziar Mike Doustdar appears confident in his commercial and R&amp;D battle plan for the coming months.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm26-novo-nordisk-ceo-reflects-curse-leader-company-looks-reassert-glp-1-footing)

---

### ğŸ‡ºğŸ‡¸ STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 21:03

> The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 17:00

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Trump releases health care plan amid pressure over affordability

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 18:10

> Trump's most consequential proposals would require action from Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/15/trump-great-healthcare-plan-potential-stumbling-blocks/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y.

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 17:55

> The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a Covid-era contract.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/covid-insider-trading-stock-emergent-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 01:29

> A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/14/pharmacy-compounder-antitrust-lilly-novo-weight-obesity/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: HHS dismisses members of vaccine injury advisory panel

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-13 21:24

> RFK Jr. is considering changes to the federal vaccine injury compensation program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/13/hhs-dismisses-veronica-mcnally-advisory-commission-on-childhood-vaccinations/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: At JPM 2026, Mehmet Oz and top Trump health officials explain their thinking to hospital leaders

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-13 16:32

> Oz downplayed the effects of cuts to Medicaid and defended RFK Jr.'s moves on vaccines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/13/jpm-2026-cms-officials-face-off-hospital-insurance-execs/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Illumina launches massive cell atlas to fast-track drug discovery

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-13 13:15

> The genomics juggernaut Illumina has launched a massive cell atlas to fast-track drug discovery.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/13/illumina-billion-cell-atlas-ai-drug-development/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Unitaid will provide funds for South Africa and Zambia to widen access to Gileadâ€™s HIV prevention drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-13 11:00

> Unitaid will provide funds for South Africa and Zambia to widen access to Gilead's HIV prevention drug.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/13/aids-hiv-gilead-unitaid-africa-lenacapavir/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Trump administration indicates it will drop appeal of a court order blocking a 340B pilot program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-12 19:59

> The Trump administration has signaled plans to drop its appeal of a court order that blocked a pilot from changing payment terms for the 340B drug discount program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/12/hospitals-pharma-medicines-340b-court-rebates/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Makary talks FDA's plans to combat China's biotech growth

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 19:51
- **é‡è¦æ€§**: â­â­â­â­

> As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/)

---

### ğŸ‡ºğŸ‡¸ The newest womenâ€™s health unicorn

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 19:00
- **é‡è¦æ€§**: â­â­â­â­

> Last week, Pomelo Care kicked off the year by raising $92 million in a Series C round that valued it at $1.7 billion â€” becoming digital healthâ€™s first newly minted unicorn of 2026, by my count ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/the-newest-womens-health-unicorn/)

---

### ğŸ‡ºğŸ‡¸ Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 08:30
- **é‡è¦æ€§**: â­â­â­â­

> The Novo Nordisk Foundation is committing 5.5 billion Danish krone ($857 million) to a life science and deep tech incubator called the BioInnovation Institute from 2026 through 2035. The funding will allow the institute, also ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novo-nordisk-foundation-to-inject-850m-into-bioinnovation-institute-through-2035/)

---

### ğŸ‡ºğŸ‡¸ Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 16:24
- **é‡è¦æ€§**: â­â­

> More than 3,000 prescriptions were written for Novo&rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/)

---

### ğŸ‡ºğŸ‡¸ JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharmaâ€™s cell therapy view

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-14 19:59
- **é‡è¦æ€§**: â­â­

> Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/jpm26-biotech-ipos-novo-wegovy-gsk-cell-therapy/809600/)

---

### ğŸ‡ºğŸ‡¸ Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-14 16:51
- **é‡è¦æ€§**: â­â­

> Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a &ldquo;rapid review&rdquo; for orforglipron that's currently speeding along &ldquo;at pace.&rdquo;&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/)

---

### ğŸ‡ºğŸ‡¸ Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 22:05
- **é‡è¦æ€§**: â­â­

> SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/)

---

### ğŸ‡ºğŸ‡¸ Drugmakers without MFN pacts are bracing to make one

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:48
- **é‡è¦æ€§**: â­â­

> All but 17 drugmakers avoided a direct demand from President Donald Trump last year to lower their prices significantly. But that likely wonâ€™t last. There was a subtle unease among executives of some of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/drugmakers-without-mfn-pacts-are-bracing-to-make-one/)

---

### ğŸ‡ºğŸ‡¸ European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 12:10
- **é‡è¦æ€§**: â­â­

> The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/european-regulators-recommended-38-novel-drugs-in-2025-15-fewer-than-the-fda/)

---

### ğŸ‡ºğŸ‡¸ FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 13:52
- **é‡è¦æ€§**: â­â­

> The FDA is set to meet with Novo Nordisk sometime early this year to discuss the progress made at its troubled Indiana facility, formerly run by Catalent. This is according to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-to-meet-novo-nordisk-on-troubled-site-abbvie-buys-drug-device-factory/)

---

### ğŸ‡ºğŸ‡¸ Scribe Therapeutics plans to test cholesterol-lowering therapy this summer

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-14 21:11
- **é‡è¦æ€§**: â­â­

> Scribe Therapeutics, founded almost nine years ago to develop medicines based on novel CRISPR enzymes, is getting ready to test its first therapy in the clinic this summer, the gene editing startup told Endpoints News ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/scribe-therapeutics-plans-to-test-cholesterol-lowering-therapy-this-summer/)

---

### ğŸ‡ºğŸ‡¸ Health tech funding rounds get bigger when Andreessen Horowitz and General Catalyst join

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-14 18:43
- **é‡è¦æ€§**: â­â­

> A few venture capital firms make up a significant portion of health tech startup funding, a report by digital health consultancy Rock Health found. The split between startups landing megarounds of over ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/health-tech-funding-rounds-get-bigger-when-andreessen-horowitz-and-general-catalyst-join/)

---

### ğŸ‡ºğŸ‡¸ AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 21:01
- **é‡è¦æ€§**: â­

> AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/)

---

### ğŸ‡ºğŸ‡¸ ImmunityBio's cell therapy posts encouraging early data in rare blood cancer

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 16:05
- **é‡è¦æ€§**: â­

> ImmunityBioâ€™s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with WaldenstrÃ¶m non ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/)

---

### ğŸ‡ºğŸ‡¸ Ocugen touts Phase 2 data for eye disease gene therapy

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 13:15
- **é‡è¦æ€§**: â­

> Eye disease gene therapy developer Ocugen reported positive interim Phase 2 data for its geographic atrophy program from a small number of patients. Researchers were testing two different dose levels of the experimental therapy, which ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ocugen-touts-phase-2-data-for-eye-disease-gene-therapy/)

---

### ğŸ‡ºğŸ‡¸ J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer setting

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 11:52
- **é‡è¦æ€§**: â­

> Johnson &amp; Johnsonâ€™s Tecvayli has achieved survival outcomes in a Phase 3 trial that bode well for its ambitions to expand its use to earlier lines of multiple myeloma. The MajesTEC-9 study enrolled patients with ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jj-reports-positive-phase-3-data-for-tecvayli-in-earlier-blood-cancer-setting/)

---

### ğŸ‡ºğŸ‡¸ On biotechâ€™s biggest stage, renewed excitement gets a stress test

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 11:43

> A surge in deals and financings had the industry abuzz heading into this year&rsquo;s J.P. Morgan Healthcare Conference. But some aren&rsquo;t sure if the rebound is here to stay.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/)

---

### ğŸ‡ºğŸ‡¸ Trump unveils healthcare affordability plan

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 20:30

> The &ldquo;Great Healthcare Plan&rdquo; is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-great-healthcare-plan-affordability-aca/809779/)

---

### ğŸ‡ºğŸ‡¸ Tecvayli tops standard drugs in early multiple myeloma, J&J says

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 16:32

> The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&amp;J a new kind of drug review voucher.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/johnson-johnson-tecvayli-early-multiple-myeloma-majestec-results/809721/)

---

### ğŸ‡ºğŸ‡¸ Oxford Biomedica confirms takeover talks with biotech investor EQT

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 16:06

> Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited take-private bids from EQT that it felt &ldquo;undervalued&rdquo; the company and its prospects.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/oxford-biomedica-eqt-offer-acquire-cell-gene-therapy/809705/)

---

### ğŸ‡ºğŸ‡¸ Boston Scientific to acquire Penumbra for $14.5B

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 15:47

> With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/boston-scientific-acquire-penumbra/809737/)

---

### ğŸ‡ºğŸ‡¸ Caldera starts up with $112.5M and a dual-targeting immune drug from China

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-14 15:50

> The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/caldera-biotech-startup-qyuns-ibd-drug-tl1a-il23/809577/)

---

### ğŸ‡ºğŸ‡¸ JPM26: Biotechâ€™s M&A lift, the â€˜newâ€™ Biogen and Merckâ€™s $70B target

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-13 21:45

> Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/)

---

### ğŸ‡ºğŸ‡¸ JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-17 11:00

> Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/)

---

### ğŸ‡ºğŸ‡¸ Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:06

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/supreme-court-will-hear-hikmas-skinny-label-fight-against-amarin/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 14:42

> SAN FRANCISCO â€” Throughout his 53 meetings at this year's JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone's minds. "We're going to put a cup in the middle of ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/)

---

### ğŸ‡ºğŸ‡¸ Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 12:00

> â†’ These days, itâ€™s just not Peer Review without Novo Nordisk: Anja Leth Zimmer said on LinkedIn that she had been promoted to chief AI officer at the Danish pharma, which ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novo-nordisk-biomarin-make-ai-moves-bristol-myers-welcomes-neurology-exec-from-eisai/)

---

### ğŸ‡ºğŸ‡¸ New York sues ex-Emergent CEO over insider trading during vaccine manufacturing struggle

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 20:36

> New York prosecutors sued the former CEO of Emergent BioSolutions over alleged insider trading while the contract manufacturer struggled with contamination issues making AstraZeneca's Covid-19 vaccine during the pandemic. The lawsuit ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/new-york-sues-ex-emergent-ceo-over-insider-trading-during-vaccine-manufacturing-struggle/)

---

### ğŸ‡ºğŸ‡¸ Trump asks Congress to codify â€˜most favored nationâ€™ deals

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 19:10

> President Donald Trump wants new legislation that cements his "most favored nation" deals with drugmakers, asking Congress to put the drug price discounts into law that the pharma industry has so far voluntarily agreed to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/trump-asks-congress-to-codify-most-favored-nation-deals/)

---

### ğŸ‡ºğŸ‡¸ A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 17:42

> Eli Lilly and Novo Nordisk have waged a bitter legal campaign against compounding pharmacies that have churned out custom versions of their blockbuster obesity drugs over the last couple of years. Now, one is fighting ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/a-compounding-pharmacy-hits-back-at-eli-lilly-novo-nordisk-with-antitrust-lawsuit/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Inside Fosun Pharma's ambition to reach outside of China

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 16:31

> SAN FRANCISCO â€” Shanghai Fosun Pharmaceutical, a major Chinese healthcare manufacturer, aims to build itself into a global drug innovator, an executive with the company told Endpoints News at the JP Morgan Healthcare Conference. ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/inside-fosun-pharmas-ambition-to-reach-outside-of-china/)

---

### ğŸ‡ºğŸ‡¸ Alfasigma gains neuro treatment; BridgeBio offers $550M in notes

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 15:48

> Plus, news about Insmed: ğŸ§  Alfasigma strikes deal for neurological disease treatment: The pharma company has secured global rights to the parenteral formulation of Innovative Moleculesâ€™ drug candidate adibelivir for Herpes ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/alfasigma-gains-neuro-treatment-bridgebio-offers-550m-in-notes/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Manufacturers benefit as pharma customers invest back in US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-14 20:19

> The tariff and trade policy changes that made 2025 so tumultuous for pharmaceutical companies are shaping up to bring benefits in the year ahead now that there's more clarity, according to manufacturers at the annual ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/manufacturers-benefit-as-pharma-customers-invest-back-in-us/)

---

### ğŸ‡ºğŸ‡¸ Jazz sells priority review voucher for $200M, scoring highest price in a decade

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-14 18:44

> Jazz Pharmaceuticals said it sold a priority review voucher to an undisclosed company for $200 million, landing the highest price for such a voucher since 2016. Jazz will take home half ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jazz-sells-priority-review-voucher-for-200m-scoring-highest-price-in-a-decade/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Verified Clinical Benefit | Cancer Accelerated Approvals

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:17
- **é‡è¦æ€§**: â­â­â­

> This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)

---

### ğŸ‡ºğŸ‡¸ Drug Safety Oversight Board

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:17
- **é‡è¦æ€§**: â­â­

> The DSB is composed of representatives from two FDA Centers and eight other federal government agencies, the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Defense.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board)

---

### ğŸ‡ºğŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:13
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ğŸ‡ºğŸ‡¸ Resources for Biomarker Requestors

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:11
- **é‡è¦æ€§**: â­â­

> Information and resources for requestors about FDAâ€™s Biomarker Qualification Program

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors)

---

### ğŸ‡ºğŸ‡¸ Tips for Section 804 Importation Program Proposals (SIPs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 18:39
- **é‡è¦æ€§**: â­â­

> FDAâ€™s tips for section 804 state importation program (SIP) proposals provide information to assist states and tribes develop their proposals.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/tips-section-804-importation-program-proposals-sips)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program Policies and Authorizations

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:17
- **é‡è¦æ€§**: â­â­

> FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program (SIP) Proposals and FDAâ€™s Review Process

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:13
- **é‡è¦æ€§**: â­â­

> Section 804 of the Federal Food, Drug and Cosmetic Act allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs without imposing additional risk to public health and safety.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-sip-proposals-and-fdas-review-process)

---

### ğŸ‡ºğŸ‡¸ Importation Program under Section 804 of the FD&C Act

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:13
- **é‡è¦æ€§**: â­â­

> FDA has developed a pathway under section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) that allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-imports/importation-program-under-section-804-fdc-act)

---

### ğŸ‡ºğŸ‡¸ FDA Authorizes Floridaâ€™s Drug Importation Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:04
- **é‡è¦æ€§**: â­â­

> FDA authorized Floridaâ€™s Agency for Health Care Administrationâ€™s Section 804 Importation Program (SIP) in accordance with section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and the FDAâ€™s implementing regulations.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/press-announcements/fda-authorizes-floridas-drug-importation-program)

---

### ğŸ‡ºğŸ‡¸ State Importation Program Enhancements

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 16:54
- **é‡è¦æ€§**: â­â­

> FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/reports/state-importation-program-enhancements)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:01
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ My Dog Has Cancer: What Do I Need to Know?

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 13:44
- **é‡è¦æ€§**: â­â­

> Just as FDA reviews drugs for humans for safety and effectiveness before they can go on the market, the agency does the same for treatments for animals. Learn how FDA brings new oncology treatments to market and questions to ask your vet about your dog's cancer diagnosis.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know)

---

### ğŸ‡ºğŸ‡¸ Field Science - Laboratory Manual

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-15 20:02
- **é‡è¦æ€§**: â­â­

> The Laboratory Manual is a reference manual for FDA personnel. It provides FDA personnel with information on internal procedures to be used as an agency policy for testing consumer products, training of laboratory staff, report writing, safety, research, review of private laboratory reports and cour

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/science-research/field-science-and-laboratories/field-science-laboratory-manual)

---

### ğŸ‡ºğŸ‡¸ Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 â€“ present

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 18:40
- **é‡è¦æ€§**: â­

> The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 23:19

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program Quality Assurance Tool

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:14

> This quality assurance (QA) tool is designed to assist section 804 importation program (SIP) sponsors prepare proposals that fully comply with the requirements under the final rule.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-quality-assurance-tool)

---

### ğŸ‡ºğŸ‡¸ Human Drug Imports

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 16:53

> Human drug import information including PLAIR, safe importation action plan, and personal importation policy.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-imports)

---

### ğŸ‡ºğŸ‡¸ Recently Issued Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:59

> This page lists Recently Issued CBER and Cross-Center Guidance Documents.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 14:47

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Office of New Drugs Custom Medical Queries (OCMQs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-15 20:43

> Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/office-new-drugs-custom-medical-queries-ocmqs)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ Argenx receives review from FDA for VYVGART in seronegative gMG

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-14 11:54
- **é‡è¦æ€§**: â­â­â­

> Regulator accepts supplemental application supported by positive phase 3 data

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argenx-receives-review-from-fda-for-vyvgart-in-seronegative-gmg/)

---

### ğŸ‡ºğŸ‡¸ Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:34
- **é‡è¦æ€§**: â­â­

> Decision introduces zolbetuximab for eligible patients in NHS Scotland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/)

---

### ğŸ‡ºğŸ‡¸ PMGroup Worldwide Ltd welcomes MAD World Summit

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-14 12:01
- **é‡è¦æ€§**: â­â­

> Acquisition expands PMGroupâ€™s commitment to transforming workplace health and organisational resilience

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/pmgroup-worldwide-ltd-welcomes-mad-world-summit/)

---

### ğŸ‡ºğŸ‡¸ Nuclera extends Series C funding to advance antibody engineering

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-13 13:52
- **é‡è¦æ€§**: â­â­

> Investment to accelerate development of fullâ€‘format antibody capabilities on eProtein Discovery system

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/nuclera-extends-series-c-funding-to-advance-antibody-engineering/)

---

### ğŸ‡ºğŸ‡¸ Ipsen announces new data on Dysport in neurological disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:55

> Dysport reduces muscle contractions by blocking the transmission of nerve impulses

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ipsen-announces-new-data-on-dysport-in-neurological-disease/)

---

### ğŸ‡ºğŸ‡¸ Jurgen Berendsen

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:54

> Symeres has appointed Jurgen Berendsen as Chief Financial Officer (CFO).

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/jurgen-berendsen/)

---

### ğŸ‡ºğŸ‡¸ True colours

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 10:09

> The gold standard in spectroscopy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/web_exclusives/true-colours/)

---

### ğŸ‡ºğŸ‡¸ Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-13 10:53

> New manufacturing technologies aim to accelerate next-generation cell therapy development

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/cellistic-launches-new-ipsc-based-platforms-to-expand-immuno-oncology-therapies/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-19 14:40:37*